1. Academic Validation
  2. Tetrahydropyrimidine Ionizable Lipids for Efficient mRNA Delivery

Tetrahydropyrimidine Ionizable Lipids for Efficient mRNA Delivery

  • ACS Nano. 2024 Oct 22;18(42):29045-29058. doi: 10.1021/acsnano.4c10154.
Ivan Isaac 1 Altab Shaikh 1 Mayurakkhi Bhatia 1 Qian Liu 2 3 Seungman Park 4 5 Chandrabali Bhattacharya 1 5
Affiliations

Affiliations

  • 1 Department of Chemistry and Biochemistry, University of Nevada, Las Vegas, Las Vegas, Nevada 89154, United States.
  • 2 Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, Las Vegas, Nevada 89154, United States.
  • 3 School of Life Sciences, College of Sciences, University of Nevada, Las Vegas, Las Vegas, Nevada 89154, United States.
  • 4 Department of Mechanical Engineering, University of Nevada, Las Vegas, Las Vegas, Nevada 89154, United States.
  • 5 Interdisciplinary Biomedical Engineering Program, University of Nevada, Las Vegas, Las Vegas, Nevada 89154, United States.
Abstract

Lipid nanoparticles (LNPs) have emerged as an effective and promising technology for messenger RNA (mRNA) delivery, offering a potential solution to physiological barriers and providing an alternative approach to gene therapy without the drawbacks associated with viral delivery. However, efficiently delivering mRNA remains a significant challenge in nucleic acid-based therapies due to the limitations of current LNP platforms in achieving optimal endosomal escape and mRNA release, which largely relies on finding a suitable ionizable lipid. Additionally, the synthesis of these ionizable lipids involves multiple chemical reactions, often making the process time-consuming and difficult to translate. In this study, we employed a facile, catalyst-free, and versatile one-pot multicomponent reaction (MCR) to develop a library of ionizable lipids featuring a pharmacologically significant tetrahydropyrimidine (THP) backbone, tailored for enhanced mRNA delivery. A library of 26 THP ionizable lipids was systematically synthesized in just 3 h and formulated with luciferase mRNA for initial in vitro screening. The THP LNPs exhibited tunable particle sizes, favorable ζ-potentials, and high encapsulation efficiencies. Among them, THP1 demonstrated the highest transfection efficiency both in vitro and in vivo after intramuscular administration, comparable to DLin-MC3-DMA (MC3), a conventional benchmark. Further optimization of THP1 with Phospholipids significantly enhanced intramuscular mRNA delivery and showed sustained protein expression in vivo for up to 5 days. More importantly, it demonstrated successful intravenous delivery in a dose-dependent manner with minimal toxicity, as indicated by hematological, histopathological, and proinflammatory cytokine assessments. Furthermore, THP1 LNPs also demonstrated the ability to edit genes in specific liver tissues in a tdTomato transgenic mouse model, highlighting their precision and utility in targeted therapeutic applications. These findings position THP1 LNPs as promising candidates for advancing mRNA-based therapies, with significant implications for clinical translation in vaccine delivery and CRISPR/Cas9-mediated gene editing in the liver.

Keywords

biomaterials; in vivo delivery; ionizable lipid; lipid nanoparticles; mRNA; multicomponent reaction; tetrahydropyrimidine.

Figures
Products